Idera Pharmaceuticals Announces Initiation of Treatment in Phase 2 Clinical Trial of IMO-3100 for Psoriasis

Idera Pharmaceuticals, Inc.

today announced the treatment of the first patient in a Phase 2 clinical trial of IMO-3100, the Company's lead Toll-like receptor inhibitor for the treatment of autoimmune diseases, in patients with moderate to severe plaque psoriasis. IMO-3100 is an immunomodulator that inhibits the activity of TLR7 and TLR9 and modulates the production of multiple pro-inflammatory mediators, including TNF-α, INF-α, IL1-β, IP-10, IL-17, and IL-23. IMO-3100 has demonstrated potent activity in reducing pathologic and immunologic manifestations in preclinical mouse models of psoriasis. In Phase 1 studies in healthy subjects, IMO-3100 has been well tolerated at the doses administered, and has shown target engagement of TLR7 and TLR9.